Latest News

  • Alkermes to Host Conference Call to Discuss Second Quarter 2017 Financial Results Read More
  • Alkermes Announces Positive Preliminary Topline Results From Phase 3 Antipsychotic Efficacy Study of ALKS 3831 for Treatment of Schizophrenia Read More
  • Alkermes Announces Initiation of Study 217 for ALKS 5461 for Treatment of Major Depressive Disorder Read More

Investors

Learn more Learn More Alkermes PLC Investor Relations

Working at Alkermes

Join Our Team Join Our Team Working at Alkermes